US Pharmacy Price-Fixing: Judge Approves Settlement
The amended settlement agreed by 13 drugmakers in the US pharmacy pricing class-action antitrust lawsuit (Marketletters passim) has been approved by Chicago Federal Court Judge Charles Kocoras.
While "the language propounded by the amendment does not mirror precisely the language articulated by the court," he says, "we believe the amendment sufficiently addresses our state concerns and in fact represents a firm commitment on the part of the settling defendants." Settling were American Home Products, Bristol-Myers Squibb, Glaxo Wellcome, Lilly, Knoll, Merck & Co, Pfizer, Schering-Plough, SmithKline Beecham, Warner-Lambert and Zeneca.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze